

Binimetinib COLUMBUS

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life




Improved QoL

Serious and disabling adverse effects



Other adjustments



Long-term plateau in the survival curve

Binimetinib COLUMBUS

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers  
Therapeutic Indication: In combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation  
Experimental Arm: Binimetinib + Encorafenib  
Control Arm: Vemurafenib

